Johannes Czernin

Title(s)Department Vice Chair, Molecular and Medical Pharmacology
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Professor, Molecular and Medical Pharmacology

    Title(s)Professor, Medicine


    Collapse Research 
    Collapse Research Activities and Funding
    PET Imaging-guided Personalized Therapy in Pancreatic Cancer
    NIH R01CA187678Aug 18, 2014 - Jul 31, 2020
    Role: Co-Principal Investigator
    A New Theranostic System for PET Image Guided Radiotherapy of Cancer
    NIH R21CA179322Jul 1, 2013 - Jun 30, 2017
    Role: Principal Investigator
    Novel molecular imaging approaches to monitor gene and cell-based therapies
    NIH R01CA160770Sep 1, 2011 - Aug 31, 2014
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and Christine Mona About Success in Academia and Industry. J Nucl Med. 2024 Apr 04. Beekman F, Czernin J, Mona C. PMID: 38575190.
      View in: PubMed   Mentions:    Fields:    
    2. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024 Mar 16. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. PMID: 38494380.
      View in: PubMed   Mentions:    Fields:    
    3. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024 Mar 14. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. PMID: 38490855.
      View in: PubMed   Mentions:    Fields:    
    4. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024 Mar 01; 65(3):438-445. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. PMID: 38238041.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024 Jan 29. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. PMID: 38290964.
      View in: PubMed   Mentions:    Fields:    
    6. [68Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor. J Nucl Med. 2024 Jan 11. Unterrainer LM, Memarzadeh S, Moatamed NA, Benz MR, Czernin J, Calais J. PMID: 38212069.
      View in: PubMed   Mentions:    Fields:    
    7. Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis. J Nucl Med. 2024 Jan 02; 65(1):59-62. Maliha PG, Hotta M, Czernin J, Calais J. PMID: 37945382.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership. J Nucl Med. 2024 Jan 02; 65(1):1-3. Pappas V, Czernin J. PMID: 38167621.
      View in: PubMed   Mentions:    Fields:    
    9. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023 Oct 30; 13(1):95. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. PMID: 37902861; PMCID: PMC10616012.
      View in: PubMed   Mentions:
    10. Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo. J Nucl Med. 2023 11; 64(11):1671-1673. Kairemo K, Czernin J. PMID: 37857505.
      View in: PubMed   Mentions:    Fields:    
    11. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023 11; 64(11):1772-1778. Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. PMID: 37797974; PMCID: PMC10626377.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    12. Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz. J Nucl Med. 2023 10; 64(10):1506-1508. Ganz PA, Czernin J. PMID: 37788851.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. A Tribute to Our JNM Associate Editors. J Nucl Med. 2023 10; 64(10):1505. Czernin J. PMID: 37788850.
      View in: PubMed   Mentions:    Fields:    
    14. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023 11; 64(11):1737-1743. Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. PMID: 37678927.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber. J Nucl Med. 2023 Sep; 64(9):1361-1363. Delpassand ES, Rohren EM, Weber WA, Czernin J. PMID: 37591543.
      View in: PubMed   Mentions: 1     Fields:    
    16. Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States. J Nucl Med. 2023 Sep; 64(9):1359-1360. Czernin J, Calais J. PMID: 37562803.
      View in: PubMed   Mentions:    Fields:    
    17. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023 12; 84(6):588-596. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. PMID: 37482512.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    18. Leading the European Society of Cardiology: A Conversation Between Franz Weidinger, Frank Bengel, and Johannes Czernin. J Nucl Med. 2023 07; 64(7):998-1000. Weidinger F, Bengel F, Czernin J. PMID: 37399311.
      View in: PubMed   Mentions:    Fields:    
    19. PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy. J Nucl Med. 2023 09; 64(9):1502-1503. Murthy V, Allen-Auerbach M, Lam R, Owen D, Czernin J, Calais J. PMID: 37321828.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. [68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis. J Nucl Med. 2023 10; 64(10):1660-1661. Unterrainer LM, Sisk AE, Czernin J, Shuch BM, Calais J, Hotta M. PMID: 37321822.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023; 2023:2480493. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. PMID: 37333052; PMCID: PMC10275689.
      View in: PubMed   Mentions:
    22. Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [68Ga]Ga-FAPI-46 PET-Positive and [18F]FDG PET-Negative. J Nucl Med. 2023 11; 64(11):1839-1840. Maliha PG, Mendelsohn AH, Czernin J, Howard T, Calais J, Hotta M. PMID: 37230532.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin. J Nucl Med. 2023 05; 64(5):678-681. Morris MJ, Calais J, Czernin J. PMID: 37055221.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023 07; 64(7):1024-1029. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PMID: 36997329.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023 07; 132(1):65-74. Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan AU. PMID: 36797449.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    26. The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition. J Nucl Med. 2023 03; 64(3):343. Czernin J, Calais J. PMID: 36863780.
      View in: PubMed   Mentions: 1     Fields:    
    27. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023 08 01; 116(5):1079-1084. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. PMID: 36863416.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes Czernin. J Nucl Med. 2023 02; 64(2):185-187. Simeone DM, Herrmann K, Czernin J. PMID: 36725247.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. J Nucl Med. 2023 06; 64(6):869-872. Gudenkauf LM, Chavez MN, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. PMID: 36635088; PMCID: PMC10241017.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. From Physician to Leader in Global Research and Development: A Conversation Between Ken Song, Lisa Bodei, and Johannes Czernin. J Nucl Med. 2023 01; 64(1):8-11. Song K, Bodei L, Czernin J. PMID: 36599476.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Thank You Drs. Ziessman and Knight for Your Many Years of Newsline Coverage. J Nucl Med. 2023 01; 64(1):1. Czernin J. PMID: 36599472.
      View in: PubMed   Mentions:    Fields:    
    32. Incidental Focal 68Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion. J Nucl Med. 2023 06; 64(6):992. Maliha PG, Jafarvard M, Czernin J, Calais J, Hotta M. PMID: 36581376.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022 Oct 01; 12(1):65. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. PMID: 36182983; PMCID: PMC9526774.
      View in: PubMed   Mentions: 3  
    34. Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis. Immunology. 2023 01; 168(1):152-169. Chen BY, Salas JR, Trias AO, Perez Rodriguez A, Tsang JE, Guemes M, Le TM, Galic Z, Shepard HM, Steinman L, Nathanson DA, Czernin J, Witte ON, Radu CG, Schultz KA, Clark PM. PMID: 35986643; PMCID: PMC9844239.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    35. A Life in Nuclear Medicine in Israel: A Conversation Between Ora Israel and Johannes Czernin. J Nucl Med. 2022 09; 63(9):1285-1287. Israel O, Czernin J. PMID: 36215517.
      View in: PubMed   Mentions:    Fields:    
    36. A 2022 International Survey on the Status of Prostate Cancer Theranostics. J Nucl Med. 2023 01; 64(1):47-53. Beyer T, Czernin J, Freudenberg L, Giesel F, Hacker M, Hicks RJ, Krause BJ. PMID: 35953304.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken Herrmann. J Nucl Med. 2022 08; 63(8):1127-1130. Kmetyuk Y, Czernin J, Herrmann K. PMID: 35914829.
      View in: PubMed   Mentions:    Fields:    
    38. More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging. J Nucl Med. 2022 07; 63(7):969-970. Czernin J, Adams T, Calais J. PMID: 35772954.
      View in: PubMed   Mentions: 2     Fields:    
    39. 18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models. J Nucl Med. 2023 01; 64(1):117-123. Le TM, Lee HR, Abt ER, Rashid K, Creech AL, Liang K, Cui J, Cho A, Wei L, Labora A, Chan C, Sanchez E, Kriti K, Karin D, Li L, Wu N, Mona C, Carlucci G, Hugo W, Wu TT, Donahue TR, Czernin J, Radu CG. PMID: 35738905; PMCID: PMC9841248.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    40. How Many Theranostics Centers Will We Need in the United States? J Nucl Med. 2022 06; 63(6):805-806. Czernin J, Calais J. PMID: 35649664.
      View in: PubMed   Mentions: 1     Fields:    
    41. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med. 2022 11; 63(11):1651-1658. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz MR, Fendler WP, Eiber M. PMID: 35422442; PMCID: PMC9635677.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    42. Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis. J Nucl Med. 2022 10; 63(10):1484-1488. Hotta M, Gafita A, Czernin J, Calais J. PMID: 35273096.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. Health Care and Nuclear Medicine in France: A Conversation Between Dominique Le Guludec, Johannes Czernin, and Jérémie Calais. J Nucl Med. 2022 Mar; 63(3):327-330. Le Guludec D, Czernin J, Calais J. PMID: 35232878.
      View in: PubMed   Mentions:    Fields:    
    44. A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann. J Nucl Med. 2022 Feb; 63(2):169-171. Gillessen S, Czernin J, Herrmann K. PMID: 35101926.
      View in: PubMed   Mentions:    Fields:    
    45. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Cell Rep. 2022 01 11; 38(2):110236. Abt ER, Le TM, Dann AM, Capri JR, Poddar S, Lok V, Li L, Liang K, Creech AL, Rashid K, Kim W, Wu N, Cui J, Cho A, Lee HR, Rosser EW, Link JM, Czernin J, Wu TT, Damoiseaux R, Dawson DW, Donahue TR, Radu CG. PMID: 35021095; PMCID: PMC8893345.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    46. Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann. J Nucl Med. 2022 01; 63(1):1-4. Hicks R, Czernin J, Herrmann K. PMID: 34980666; PMCID: PMC8717180.
      View in: PubMed   Mentions:    Fields:    
    47. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 12 01; 4(12):e2138550. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. PMID: 34902034; PMCID: PMC8669522.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. J Nucl Med. 2022 07; 63(7):1021-1026. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. PMID: 34740953; PMCID: PMC9258565.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    49. Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin. J Nucl Med. 2021 Nov; 62(11):1492-1494. Scott AM, Czernin J. PMID: 34725232; PMCID: PMC8612318.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. J Nucl Med. 2021 Nov; 62(11):1489-1491. Calais J, Czernin J. PMID: 34725231; PMCID: PMC8612346.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    51. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Nov 01; 7(11):1635-1642. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. PMID: 34529005; PMCID: PMC8446902.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    52. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. J Nucl Med. 2022 06; 63(6):847-854. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter RE, Calais J. PMID: 34649942; PMCID: PMC9157724.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    53. PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. J Nucl Med. 2022 01; 63(1):76-80. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJH, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert M. PMID: 34620731; PMCID: PMC8717195.
      View in: PubMed   Mentions: 12     Fields:    
    54. 18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma. J Nucl Med. 2022 05; 63(5):708-712. Crompton JG, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. PMID: 34593596; PMCID: PMC9051595.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging. Proc Natl Acad Sci U S A. 2021 09 07; 118(36). Liang K, Abt ER, Le TM, Cho A, Dann AM, Cui J, Li L, Rashid K, Creech AL, Wei L, Ghukasyan R, Rosser EW, Wu N, Carlucci G, Czernin J, Donahue TR, Radu CG. PMID: 34480004; PMCID: PMC8433573.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    56. The Annual Journal Impact Factor Saga. J Nucl Med. 2021 Sep 01; 62(9):1177. Czernin J. PMID: 34475240.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    57. Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas. J Nucl Med. 2021 Sep 01; 62(9):1178-1180. Czernin J, Radu C, Ribas A. PMID: 34475241.
      View in: PubMed   Mentions:    Fields:    
    58. Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jérémie Calais. J Nucl Med. 2021 Aug 01; 62(8):1027-1030. Hofman MS, Calais J, Czernin J. PMID: 34330738.
      View in: PubMed   Mentions:    Fields:    
    59. A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. J Nucl Med. 2022 04; 63(4):567-572. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. PMID: 34326126; PMCID: PMC8973291.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    60. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2022 Feb; 63(2):199-204. Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. PMID: 34272317.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    61. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med. 2021 10; 62(10):1447-1456. Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. PMID: 34272322; PMCID: PMC8724902.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    62. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 08; 22(8):1115-1125. Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. PMID: 34246328.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    63. The Annual Journal Impact Factor Saga. J Nucl Med. 2021 Jul 08. Czernin J. PMID: 34244356.
      View in: PubMed   Mentions:    Fields:    
    64. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2022 03; 63(3):376-383. Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. PMID: 34215673; PMCID: PMC8978200.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    65. Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope. J Nucl Med. 2021 07 01; 62(7):881-883. Marzella L, Czernin J, Hope T. PMID: 34244366.
      View in: PubMed   Mentions:    Fields:    
    66. 177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine. J Nucl Med. 2021 Aug 01; 62(8):1025-1026. Czernin J, Calais J. PMID: 34330737.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    67. Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2022 02; 63(2):226-232. Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M. PMID: 34049987; PMCID: PMC8805781.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    68. Reply: PSMA-Targeted Therapeutics: A Tale About Law and Economics. J Nucl Med. 2021 10; 62(10):1483. Czernin J. PMID: 34016724.
      View in: PubMed   Mentions: 1     Fields:    
    69. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021 10; 62(10):1440-1446. Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. PMID: 34016732; PMCID: PMC8724893.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    70. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer. 2021 May 07; 21(1):512. Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, Elashoff D, Fendler WP. PMID: 33962579; PMCID: PMC8103642.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    71. 68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2021 10; 48(11):3736-3737. Hotta M, Sonni I, Benz MR, Gafita A, Bahri S, Shuch BM, Yu R, Liu ST, Czernin J, Calais J. PMID: 33914106.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    72. A Conversation Between Hong Wu and Johannes Czernin. J Nucl Med. 2021 03; 62(3):293-295. Wu H, Czernin J. PMID: 33622964.
      View in: PubMed   Mentions:    Fields:    
    73. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021 05; 48(5):1626-1638. Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K. PMID: 33604691; PMCID: PMC8113168.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    74. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2022 02; 5(1):100-103. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. PMID: 33602654; PMCID: PMC10262977.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    75. Reply: Radioguided Surgery. J Nucl Med. 2021 04; 62(4):592. Weber W, Czernin J. PMID: 33547207.
      View in: PubMed   Mentions:    Fields:    
    76. Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer. Clin Nucl Med. 2021 Feb 01; 46(2):e86-e87. Hayrapetian A, Girgis MD, Yanagawa J, French SW, Schelbert HR, Auerbach MS, Czernin J, Calais J. PMID: 32701818.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    77. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. J Nucl Med. 2021 09 01; 62(9):1244-1251. Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano R, Lira S, Booker K, Gardner L, Grogan T, Elashoff D, Allen-Auerbach M, Dahlbom M, Czernin J, Calais J. PMID: 33509974; PMCID: PMC9364769.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    78. Humana and 18F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. J Nucl Med. 2021 01; 62(1):1-2. Czernin J, Iagaru A. PMID: 33334909.
      View in: PubMed   Mentions:    Fields:    
    79. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. Eur Urol Focus. 2021 03; 7(2):238-240. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. PMID: 33386288; PMCID: PMC8057677.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    80. The Solutions Come from Science and Knowledge. J Nucl Med. 2021 02; 62(2):145. Czernin J, Radu C. PMID: 33310739.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    81. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study. J Nucl Med. 2021 08 01; 62(8):1075-1081. Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L. PMID: 33277398.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    82. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. J Nucl Med. 2021 07 01; 62(7):989-995. Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. PMID: 33277393; PMCID: PMC8882874.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    83. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. J Nucl Med. 2020 12; 61(Suppl 2):263S-272S. Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, Peterson TE, Schelbert H, Schöder H, Siegel BA, Strauss HW. PMID: 33293447.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    84. 20 Years of PET/CT: A Conversation with David Townsend and Thomas Beyer. J Nucl Med. 2020 11; 61(11):1541-1543. Townsend D, Beyer T, Czernin J. PMID: 33139396.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    85. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Res. 2020 Oct 15; 10(1):122. Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N. PMID: 33063147; PMCID: PMC7561652.
      View in: PubMed   Mentions: 1  
    86. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. Eur Urol Oncol. 2022 10; 5(5):544-552. Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J. PMID: 32958451.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    87. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging. 2021 02; 48(2):501-508. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. PMID: 32808077; PMCID: PMC7835157.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    88. The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year. J Nucl Med. 2020 08; 61(8):1087. Czernin J. PMID: 32747506.
      View in: PubMed   Mentions:    Fields:    
    89. A Conversation Between Kelsey Martin and Johannes Czernin. J Nucl Med. 2020 08; 61(8):1091-1093. Martin KC, Czernin J. PMID: 32747508.
      View in: PubMed   Mentions:    Fields:    
    90. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. Eur J Nucl Med Mol Imaging. 2021 03; 48(3):924-926. Sonni I, Lee-Felker S, Memarzadeh S, Quinn MM, Mona CE, Lückerath K, Czernin J, Calais J. PMID: 32651662.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    91. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. J Nucl Med. 2021 02; 62(2):228-231. Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. PMID: 32646877.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    92. Unacceptable Denials. J Nucl Med. 2020 07; 61(7):939. Czernin J, Allen-Auerbach M. PMID: 32611710.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. The Impact of COVID-19 on the Health-Care Workforce: from Heroes to Zeroes? J Nucl Med. 2020 08; 61(8):1104. Czernin J. PMID: 32591489; PMCID: PMC7413227.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    94. Reply: Diversity, Not Divisiveness, Is the Future of Nuclear Medicine. J Nucl Med. 2020 08; 61(8):1266-1267. Czernin J. PMID: 32576638.
      View in: PubMed   Mentions:    Fields:    
    95. Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020 08; 78(2):148-154. Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, Calais J, Rauscher I, Rathke H, Tauber R, Delpassand ES, Weber WA, Herrmann K, Czernin J, Eiber M, Hofman MS. PMID: 32532512.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    96. Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright. J Nucl Med Technol. 2020 Jun; 48(Suppl 1):82S-83S. Czernin J, Calais J. PMID: 32605963.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Two Leaders. J Nucl Med. 2020 06; 61(6):773. Czernin J. PMID: 32499278.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    98. A Conversation Between Howard Soule and Johannes Czernin. J Nucl Med. 2020 06; 61(6):774-776. Soule HR, Czernin J. PMID: 32499279.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. A Conversation Between Johnese Spisso and Johannes Czernin. J Nucl Med. 2020 06; 61(6):777-779. Spisso J, Czernin J. PMID: 32385168.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    100. Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. J Nucl Med. 2020 12; 61(12):1793-1799. Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, Herrmann K, Calais J, Hope TA. PMID: 32358094; PMCID: PMC9364898.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    101. Editor's Page: Unacceptable Denials. J Nucl Med. 2020 May 01. Czernin J, Allen-Auerbach M. PMID: 32358085.
      View in: PubMed   Mentions:    Fields:    
    102. The Standard of Care: From Nuclear Radiology to Nuclear Medicine. J Nucl Med. 2020 05; 61(5):637. Czernin J. PMID: 32358174.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    103. A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope. J Nucl Med. 2020 04; 61(4):477-479. Sunderland JJ, Czernin J, Hope T. PMID: 32238494.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. J Nucl Med. 2020 05; 61(5):626-629. Czernin J, Fanti S, Meyer PT, Allen-Auerbach M, Hacker M, Sathekge M, Hicks R, Scott AM, Hatazawa J, Yun M, Schöder H, Bartenstein P, Herrmann K. PMID: 32238430.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsPHPublic Health
    105. Dr. Li Wenliang and the Time of COVID-19. J Nucl Med. 2020 05; 61(5):625. Czernin J. PMID: 32238428.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    106. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance. Mol Imaging Biol. 2020 04; 22(2):256-264. Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M. PMID: 31240531.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias. RSC Med Chem. 2020 Mar 01; 11(3):392-410. Sun DL, Poddar S, Pan RD, Rosser EW, Abt ER, Van Valkenburgh J, Le TM, Lok V, Hernandez SP, Song J, Li J, Turlik A, Chen X, Cheng CA, Chen W, Mona CE, Stuparu AD, Vergnes L, Reue K, Damoiseaux R, Zink JI, Czernin J, Donahue TR, Houk KN, Jung ME, Radu CG. PMID: 33479645; PMCID: PMC7593890.
      View in: PubMed   Mentions: 3  
    108. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study. Theranostics. 2020; 10(6):2612-2620. Stuparu AD, Meyer CAL, Evans-Axelsson SL, Lückerath K, Wei LH, Kim W, Poddar S, Mona CE, Dahlbom M, Girgis MD, Radu CG, Czernin J, Slavik R. PMID: 32194823; PMCID: PMC7052903.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    109. Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. J Neurooncol. 2020 Mar; 147(1):135-145. Oughourlian TC, Yao J, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 31981013; PMCID: PMC7080591.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    110. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity. Clin Cancer Res. 2020 06 15; 26(12):2946-2955. Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. PMID: 31932492; PMCID: PMC7299755.
      View in: PubMed   Mentions: 42     Fields:    Translation:AnimalsCells
    111. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med. 2020 08; 61(8):1153-1160. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. PMID: 31924715; PMCID: PMC7413232.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    112. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2020 08; 61(8):1171-1177. Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. PMID: 31836685; PMCID: PMC7413240.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    113. Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. EJNMMI Res. 2019 Dec 02; 9(1):103. Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. PMID: 31792771; PMCID: PMC6889088.
      View in: PubMed   Mentions: 6  
    114. Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments. J Nucl Med. 2019 12; 60(12):1657-1658. Czernin J, Allen-Auerbach M, Calais J. PMID: 31792126.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    115. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chem Biol. 2020 02 20; 27(2):197-205.e6. Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, Damoiseaux R, Czernin J, Donahue TR, Lavie A, Radu CG. PMID: 31734178; PMCID: PMC7035983.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    116. A Conversation Between Uwe Haberkorn and Johannes Czernin. J Nucl Med. 2019 Nov; 60(11):1495-1498. Haberkorn U, Czernin J. PMID: 31676705.
      View in: PubMed   Mentions:    Fields:    
    117. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply. Lancet Oncol. 2019 11; 20(11):e609-e610. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. PMID: 31674314.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    118. A Conversation Between Elisabeth de Vries and Johannes Czernin. J Nucl Med. 2019 10; 60(10):1337-1339. de Vries E, Czernin J. PMID: 31575716.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2020 03; 61(3):405-411. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. PMID: 31541035; PMCID: PMC7067527.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    120. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 12 15; 25(24):7448-7454. Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. PMID: 31511295.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    121. The Future of Nuclear Medicine as an Independent Specialty. J Nucl Med. 2019 09; 60(Suppl 2):3S-12S. Czernin J, Sonni I, Razmaria A, Calais J. PMID: 31481589.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    122. A Conversation Between Joanna Fowler and Johannes Czernin. J Nucl Med. 2019 Sep; 60(9):1191-1193. Fowler JS, Czernin J. PMID: 31481591.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    123. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019 Nov; 46(12):2536-2544. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. PMID: 31440799.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    124. Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs. J Nucl Med. 2019 Aug; 60(8):1037. Czernin J. PMID: 31371618.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    125. A Conversation Between Hedvig Hricak and Johannes Czernin. J Nucl Med. 2019 Aug; 60(8):1038-1041. Hricak H, Czernin J. PMID: 31371619.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    126. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 09; 20(9):1286-1294. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. PMID: 31375469; PMCID: PMC7469487.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCTClinical Trials
    127. Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? J Nucl Med. 2020 02; 61(2):189-193. Rauscher I, Fendler WP, Hope TA, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M. PMID: 31324710; PMCID: PMC8801954.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    128. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):856-863. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. PMID: 30920593; PMCID: PMC6567829.
      View in: PubMed   Mentions: 231     Fields:    Translation:HumansCTClinical Trials
    129. A Conversation Between Nora Volkow and Johannes Czernin. J Nucl Med. 2019 Jun; 60(6):717-720. Volkow N, Czernin J. PMID: 31160430; PMCID: PMC6910640.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    130. A Conversation Between Markus Schwaiger and Johannes Czernin. J Nucl Med. 2019 05; 60(5):573-576. Schwaiger M, Czernin J. PMID: 31043502.
      View in: PubMed   Mentions:    Fields:    
    131. Discussions with Leaders: A Conversation between Simon Cherry and Johannes Czernin. J Nucl Med. 2019 03; 60(3):295-298. Cherry SR, Czernin J. PMID: 30824670.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    132. Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 01 21; 19(1):97. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30665383; PMCID: PMC6341574.
      View in: PubMed   Mentions:    Fields:    
    133. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 Jan 07; 19(1):18. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30616601; PMCID: PMC6322287.
      View in: PubMed   Mentions: 39     Fields:    
    134. Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives. J Nucl Med. 2019 01; 60(1):1-2. Razmaria A, Calais J, Czernin J. PMID: 30602593.
      View in: PubMed   Mentions:    Fields:    
    135. Discussions with Leaders: A Conversation Between Richard Wahl and Johannes Czernin. J Nucl Med. 2019 01; 60(1):3-6. Wahl RL, Czernin J. PMID: 30602594.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    136. Discussions with Leaders: A Conversation Between Sam Gambhir and Johannes Czernin. J Nucl Med. 2018 12; 59(12):1783-1785. Czernin J, Gambhir SS. PMID: 30510073.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    137. Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging. J Nucl Cardiol. 2019 12; 26(6):2018-2030. Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, Sparks R, Phelps M, Lazewatsky J. PMID: 30488323.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    138. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018 Oct 29; 8(1):96. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. PMID: 30374743; PMCID: PMC6206308.
      View in: PubMed   Mentions: 38  
    139. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2019 02; 17(1):e53-e55. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. PMID: 30293922.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    140. The Quality and Impact of JNM. J Nucl Med. 2018 09; 59(9):1337. Czernin J. PMID: 30181230.
      View in: PubMed   Mentions:    Fields:    
    141. Is This Whom We Have Become? J Nucl Med. 2018 Aug; 59(8):1171. Czernin J. PMID: 30072475.
      View in: PubMed   Mentions:    Fields:    
    142. Aetna and 68Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others". J Nucl Med. 2018 05; 59(5):721-722. Czernin J, Ceci F. PMID: 29717082.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    143. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neurooncol. 2018 Sep; 139(2):399-409. Patel CB, Fazzari E, Chakhoyan A, Yao J, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. PMID: 29679199; PMCID: PMC6092195.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    144. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 11; 59(11):1714-1721. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. PMID: 29653978; PMCID: PMC6225538.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    145. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med. 2018 09; 59(9):1392-1397. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. PMID: 29602819; PMCID: PMC6910618.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    146. The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders. J Nucl Med. 2018 03; 59(3):379. Czernin J. PMID: 29497001.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    147. The National Oncology PET Registry (NOPR): A monumental effort by a few leaders. J Nucl Med. 2018 Jan 25. Czernin J. PMID: 29371409.
      View in: PubMed   Mentions:    Fields:    
    148. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 29242398; PMCID: PMC5868499.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    149. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 02; 59(2):230-237. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. PMID: 29123013; PMCID: PMC5807533.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    150. Is 16 Months of Specialized Nuclear Medicine Training Enough for Best Patient Care? J Nucl Med. 2017 10; 58(10):1535. Czernin J. PMID: 28970350.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    151. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10220-10225. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. PMID: 28874539; PMCID: PMC5617282.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    152. Activation of the "Splenocardiac Axis" by electronic and tobacco cigarettes in otherwise healthy young adults. Physiol Rep. 2017 Sep; 5(17). Boas Z, Gupta P, Moheimani RS, Bhetraratana M, Yin F, Peters KM, Gornbein J, Araujo JA, Czernin J, Middlekauff HR. PMID: 28899908; PMCID: PMC5599858.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    153. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. 2017 08 14; 8(1):241. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. PMID: 28808226; PMCID: PMC5556071.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    154. The Impact of the Impact Factor. J Nucl Med. 2017 08; 58(8):1185. Czernin J. PMID: 28765226.
      View in: PubMed   Mentions:    Fields:    
    155. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. J Nucl Med. 2017 11; 58(11):1786-1792. Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. PMID: 28546332; PMCID: PMC6944167.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    156. Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail? J Nucl Med. 2017 08; 58(8):1186-1187. Czernin J, Eiber M. PMID: 28473599.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    157. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 11; 58(11):1793-1796. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. PMID: 28473600; PMCID: PMC5666645.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    158. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017 10; 58(10):1617-1623. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. PMID: 28408531.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    159. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017 01 18; 9(373). Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS. PMID: 28100832; PMCID: PMC5260938.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCellsCTClinical Trials
    160. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Rep. 2017 01 17; 18(3):601-610. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. PMID: 28099841; PMCID: PMC5260616.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimalsCells
    161. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med. 2017 May; 58(5):756-761. Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP. PMID: 28082438.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    162. Molecular Imaging and Therapy with a Purpose: A Renaissance of Nuclear Medicine. J Nucl Med. 2017 01; 58(1):21A-22A. Czernin J. PMID: 28062715.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    163. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients. Nucl Med Commun. 2016 Dec; 37(12):1290-1296. Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K. PMID: 27612034; PMCID: PMC5077695.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    164. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. J Nucl Med. 2017 03; 58(3):374-378. Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K. PMID: 27811125; PMCID: PMC6945110.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    165. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn. 2016 11; 16(11):1177-1188. Barrio M, Fendler WP, Czernin J, Herrmann K. PMID: 27679869.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    166. A Study on the Basic Criteria for Selecting Heterogeneity Parameters of F18-FDG PET Images. PLoS One. 2016; 11(10):e0164113. Forgacs A, Pall Jonsson H, Dahlbom M, Daver F, D DiFranco M, Opposits G, K Krizsan A, Garai I, Czernin J, Varga J, Tron L, Balkay L. PMID: 27736888; PMCID: PMC5063296.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    167. Evaluation of Prostate Cancer with 11C-Acetate PET/CT. J Nucl Med. 2016 Oct; 57(Suppl 3):30S-37S. Spick C, Herrmann K, Czernin J. PMID: 27694168.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    168. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. J Nucl Med. 2017 02; 58(2):307-311. Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal RK, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K. PMID: 27539839; PMCID: PMC5290122.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    169. Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. J Nucl Med. 2016 Dec; 57(12):2016-2021. Fendler WP, Czernin J, Herrmann K, Beyer T. PMID: 27516448; PMCID: PMC5135589.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    170. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med. 2016 Jul; 41(7):515-21. Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K. PMID: 26975008; PMCID: PMC5006491.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    171. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging. 2016 Nov; 43(12):2122-2130. Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C, Eberlein U, Buck AK, Lodi F, Cicoria G, Czernin J, Lassmann M, Fanti S, Herrmann K. PMID: 27329046; PMCID: PMC5050145.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCellsPHPublic Health
    172. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci U S A. 2016 Apr 12; 113(15):4027-32. Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG. PMID: 27035974; PMCID: PMC4839461.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    173. Introduction and Overview. J Nucl Med. 2016 Feb; 57 Suppl 1:1S-2S. Czernin J, Mankoff D. PMID: 26834097.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    174. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. J Nucl Med. 2016 Mar; 57(3):420-30. Spick C, Herrmann K, Czernin J. PMID: 26742709; PMCID: PMC5003572.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    175. Reply: Roundtable on the Future of Nuclear Medicine Training. J Nucl Med. 2015 Dec; 56(12):1969-70. Czernin J. PMID: 26429954.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    176. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Mol Imaging Biol. 2015 Jun; 17(3):434-42. Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. PMID: 25465392.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    177. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015 Jun; 56(6):855-61. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. PMID: 25883128; PMCID: PMC5003538.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    178. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. J Nucl Med. 2015 Jan; 56(1):70-5. Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. PMID: 25500825; PMCID: PMC5068919.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    179. Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. J Nucl Med. 2014 Dec; 55(12):1925-9. Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach MS. PMID: 25453041; PMCID: PMC4324619.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    180. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014 Oct; 55(10):1611-6. Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Löhr M, Herrmann K. PMID: 25125481.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    181. INDs for PET molecular imaging probes-approach by an academic institution. Mol Imaging Biol. 2014 Aug; 16(4):441-8. Mosessian S, Duarte-Vogel SM, Stout DB, Roos KP, Lawson GW, Jordan MC, Ogden A, Matter C, Sadeghi S, Mills GQ, Schelbert HR, Radu CG, Czernin J, Couto M, Phelps ME. PMID: 24733693; PMCID: PMC4097325.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    182. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014 Jul 28; 6(7):480-5. Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 25071888; PMCID: PMC4109099.
      View in: PubMed   Mentions: 4  
    183. Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET. J Nucl Med. 2014 Sep; 55(9):1438-44. Packard RR, Huang SC, Dahlbom M, Czernin J, Maddahi J. PMID: 25071096; PMCID: PMC4315668.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    184. Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany. Mol Imaging Biol. 2014 Jun; 16(3):295-310. Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, Franzius C, Gückel B, Handgretinger R, Hartenbach M, Hellwig D, Nadel H, Nekolla SG, Pfluger T, Pichler BJ, Quick HH, Sabri O, Sattler B, Schäfer J, Schick F, Siegel BA, Schlemmer HP, Schwenzer NF, van den Hoff J, Veit-Haibach P, Wehrl HF. PMID: 24668195.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    185. Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. J Nucl Med. 2014 Jun 01; 55(Supplement 2):59S-62S. Czernin J, Ta L, Herrmann K. PMID: 24812246.
      View in: PubMed   Mentions: 20     Fields:    
    186. Introduction. J Nucl Med. 2014 Jun 01; 55(Supplement 2):1S. Czernin J, Schwaiger M, Townsend D. PMID: 24799617.
      View in: PubMed   Mentions:    Fields:    
    187. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014 Jul 01; 20(13):3550-9. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. PMID: 24687922; PMCID: PMC4079729.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    188. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. PMID: 24634374; PMCID: PMC4070853.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    189. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J Exp Med. 2014 Mar 10; 211(3):473-86. Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG. PMID: 24567448; PMCID: PMC3949575.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCellsPHPublic Health
    190. Three-phase bone scintigraphy for imaging osteoradionecrosis of the jaw. Clin Nucl Med. 2014 Jan; 39(1):21-5. Lapa C, Linz C, Bluemel C, Mottok A, Mueller-Richter U, Kuebler A, Schneider P, Czernin J, Buck AK, Herrmann K. PMID: 24300350.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    191. Efficient radiosynthesis of 3'-deoxy-3'-18F-fluorothymidine using electrowetting-on-dielectric digital microfluidic chip. J Nucl Med. 2014 Feb; 55(2):321-8. Javed MR, Chen S, Kim HK, Wei L, Czernin J, Kim CJ, van Dam RM, Keng PY. PMID: 24365651; PMCID: PMC4494735.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    192. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol. 2014 Apr; 16(4):603-9. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. PMID: 24305722; PMCID: PMC3956344.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    193. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014 Jan; 55(1):30-6. Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W. PMID: 24167081.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansPHPublic Health
    194. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography. J Med Chem. 2013 Sep 12; 56(17):6696-708. Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG. PMID: 23947754; PMCID: PMC3789385.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    195. The potential of PET/MRI imaging in oncology: a comment to a summary report of the First PET/MRI Workshop in Tuebingen in 2012. Mol Imaging Biol. 2013 Aug; 15(4):372-3. Czernin J, Herrmann K. PMID: 23689984; PMCID: PMC3708288.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    196. PET/computed tomography and lymphoma. Radiol Clin North Am. 2013 Sep; 51(5):833-44. Allen-Auerbach M, de Vos S, Czernin J. PMID: 24010908.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    197. PET/CT in Oncology: Current Status and Perspectives. Curr Radiol Rep. 2013; 1:177-190. Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PMID: 24883234; PMCID: PMC4034170.
      View in: PubMed   Mentions: 31  
    198. Evaluation of the Genisys4, a bench-top preclinical PET scanner. J Nucl Med. 2013 Jul; 54(7):1162-7. Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, Czernin J. PMID: 23628700; PMCID: PMC3790646.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    199. High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers. Appl Radiat Isot. 2013 Aug; 78:88-101. Amaraesekera B, Marchis PD, Bobinski KP, Radu CG, Czernin J, Barrio JR, Michael van Dam R. PMID: 23702794.
      View in: PubMed   Mentions: 9     Fields:    
    200. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013 Jan 29; 61(4):469-477. Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. PMID: 23265345; PMCID: PMC4316725.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    201. From in situ to in vivo: an in situ click-chemistry-derived carbonic anhydrase II imaging agent for positron emission tomography. ChemMedChem. 2013 Jan; 8(1):43-8. Mocharla VP, Walsh JC, Padgett HC, Su H, Fueger B, Weber WA, Czernin J, Kolb HC. PMID: 23208787.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    202. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J Exp Med. 2012 Nov 19; 209(12):2215-28. Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG. PMID: 23148236; PMCID: PMC3501349.
      View in: PubMed   Mentions: 48     Fields:    Translation:AnimalsCells
    203. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clin. 2013 Apr; 8(2):201-17. Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PMID: 27157948.
      View in: PubMed   Mentions: 1     Fields:    
    204. Oncologic 18F-FDG PET/CT: referring physicians' point of view. J Nucl Med. 2012 Oct; 53(10):1499-505. Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J. PMID: 22917886.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    205. Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer. Front Oncol. 2012; 2:71. Lee P, Kupelian P, Czernin J, Ghosh P. PMID: 22798989; PMCID: PMC3393879.
      View in: PubMed   Mentions: 9  
    206. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol. 2012 Aug; 14(8):1079-89. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. PMID: 22711609; PMCID: PMC3408264.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    207. Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging. Clin Nucl Med. 2012 May; 37(5):e98-9. Karantanis D, Allen-Auerbach M, Czernin J. PMID: 22475925.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    208. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics. 2012; 2(4):374-91. Yaghoubi SS, Campbell DO, Radu CG, Czernin J. PMID: 22509201; PMCID: PMC3326723.
      View in: PubMed   Mentions: 64     Fields:    
    209. A spotlight from prostate cancer. Cancer Discov. 2012 Apr; 2(4):301-3. Herschman HR, Czernin J. PMID: 22576205.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    210. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatr Hematol Oncol. 2012 Mar; 34(2):131-6. Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N. PMID: 22134608.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    211. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012 Apr 01; 18(7):2024-31. Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. PMID: 22338012; PMCID: PMC3431618.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    212. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. J Nucl Med. 2012 Mar; 53(3):393-8. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. PMID: 22323780.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    213. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET. J Nucl Med. 2012 Feb; 53(2):275-80. Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG. PMID: 22302964; PMCID: PMC3431619.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    214. Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient? Hell J Nucl Med. 2012 Jan-Apr; 15(1):2-8. Karantanis D, Allen-Auerbach M, Czernin J. PMID: 22413105.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    215. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012 Jan; 37(1):49-53. Karantanis D, Allen-Auerbach M, Czernin J. PMID: 22157028.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    216. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012 Jan; 53(1):29-36. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. PMID: 22159180; PMCID: PMC3424269.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    217. Issues and controversies in nuclear medicine. Introduction. J Nucl Med. 2011 Dec; 52 Suppl 2:1S-2S. Czernin J, Weber WA. PMID: 22144550.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    218. Contribution of imaging to cancer care costs. J Nucl Med. 2011 Dec; 52 Suppl 2:86S-92S. Yang Y, Czernin J. PMID: 22144560.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    219. Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. J Biol Chem. 2012 Jan 02; 287(1):446-454. Campbell DO, Yaghoubi SS, Su Y, Lee JT, Auerbach MS, Herschman H, Satyamurthy N, Czernin J, Lavie A, Radu CG. PMID: 22074768; PMCID: PMC3249097.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    220. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. PMID: 22045706; PMCID: PMC5021512.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    221. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 2012 Jun 15; 118(12):3135-44. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. PMID: 22020872; PMCID: PMC3436595.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    222. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients. Pediatr Hematol Oncol. 2011 Oct; 28(7):579-87. Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J. PMID: 21936620.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    223. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011 Oct 15; 17(20):6553-62. Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. PMID: 21868765; PMCID: PMC3833447.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    224. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med. 2011 Sep; 52(9):1490-8. Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M. PMID: 21849402.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    225. The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging. 2011 06; 2(3):235-246. Beyer T, Freudenberg LS, Czernin J, Townsend DW. PMID: 22347950; PMCID: PMC3270262.
      View in: PubMed   Mentions: 20  
    226. The future of hybrid imaging-part 2: PET/CT. Insights Imaging. 2011 Jun; 2(3):225-34. Beyer T, Townsend DW, Czernin J, Freudenberg LS. PMID: 23099865; PMCID: PMC3288992.
      View in: PubMed   Mentions: 18  
    227. Practice based evidence of the beneficial impact of PET in patients with brain tumors. Mol Imaging Biol. 2011 Feb; 13(1):1-2. Macapinlac HA, Czernin J, Larson SM. PMID: 21082268.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    228. The future of hybrid imaging-part 1: hybrid imaging technologies and SPECT/CT. Insights Imaging. 2011 Apr; 2(2):161-9. Beyer T, Freudenberg LS, Townsend DW, Czernin J. PMID: 23099842; PMCID: PMC3288981.
      View in: PubMed   Mentions: 17  
    229. Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors. ChemMedChem. 2011 Apr 04; 6(4):623-7. Ng QK, Su H, Armijo AL, Czernin J, Radu CG, Segura T. PMID: 21442757; PMCID: PMC3079200.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    230. Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med. 2011 Feb; 52(2):231-40. Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA. PMID: 21233183.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    231. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med. 2011 Feb; 52(2):303-10. Beyer T, Czernin J, Freudenberg LS. PMID: 21233186.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    232. Breast cancer. Methods Mol Biol. 2011; 727:141-70. Czernin J, Benz MR, Allen-Auerbach MS. PMID: 21331933.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    233. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging. 2011 Apr; 38(4):711-21. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. PMID: 21127859; PMCID: PMC3053458.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    234. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 2010 Dec; 51(12):1826-9. Czernin J, Satyamurthy N, Schiepers C. PMID: 21078790; PMCID: PMC3169430.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansAnimals
    235. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010 Oct; 51(10):1532-8. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. PMID: 20847166.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    236. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010 Aug; 51(8):1174-81. Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J. PMID: 20660389; PMCID: PMC3197812.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    237. Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. J Nucl Med. 2010 Aug; 51(8):1285-92. Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, Phelps ME, Czernin J, Weber WA, Schiestl RH. PMID: 20660381.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    238. Novel PET probes specific for deoxycytidine kinase. J Nucl Med. 2010 Jul; 51(7):1092-8. Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG. PMID: 20554721; PMCID: PMC3119947.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    239. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma. 2010; 2010:143540. Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC. PMID: 20414348; PMCID: PMC2855986.
      View in: PubMed   Mentions: 13  
    240. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010 May; 51(5):720-7. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. PMID: 20395318.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    241. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010 Mar; 51(3):340-6. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. PMID: 20150263.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    242. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol. 2010 Mar; 73(3):470-80. Czernin J, Benz MR, Allen-Auerbach MS. PMID: 20097498.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    243. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010 Jan 15; 116(2):451-8. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC. PMID: 19924789; PMCID: PMC3188986.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    244. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A. 2010 Mar 23; 107(12):5551-6. Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG. PMID: 20080663; PMCID: PMC2851816.
      View in: PubMed   Mentions: 51     Fields:    Translation:AnimalsCells
    245. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12932-7. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. PMID: 19625624; PMCID: PMC2714280.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansAnimalsCells
    246. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009 Jul; 21(4):345-51. Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. PMID: 19412096.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    247. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A. 2009 Jul 07; 106(27):11394-9. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH, Alabi CA, Mack BC, Davis ME. PMID: 19564622; PMCID: PMC2703672.
      View in: PubMed   Mentions: 66     Fields:    Translation:AnimalsCells
    248. Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor. J Nucl Med. 2009 May; 50(5):757-64. Johnson M, Karanikolas BD, Priceman SJ, Powell R, Black ME, Wu HM, Czernin J, Huang SC, Wu L. PMID: 19372484; PMCID: PMC2805178.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    249. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15; 15(8):2856-63. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. PMID: 19351756; PMCID: PMC4068269.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    250. PET Imaging of Prostate Cancer Using C-Acetate. PET Clin. 2009 Apr; 4(2):163-72. Czernin J, Benz MR, Allen-Auerbach MS. PMID: 21984877; PMCID: PMC3188983.
      View in: PubMed   Mentions: 20     Fields:    
    251. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol. 2009 Jul-Aug; 11(4):269-74. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. PMID: 19326177; PMCID: PMC2693779.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    252. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 2009 Apr 01; 69(7):3173-9. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. PMID: 19318569; PMCID: PMC2749524.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    253. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009 Apr; 50(4):513-9. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW. PMID: 19289420.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    254. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2847-52. Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG. PMID: 19196993; PMCID: PMC2636738.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    255. A supramolecular approach for preparation of size-controlled nanoparticles. Angew Chem Int Ed Engl. 2009; 48(24):4344-8. Wang H, Wang S, Su H, Chen KJ, Armijo AL, Lin WY, Wang Y, Sun J, Kamei K, Czernin J, Radu CG, Tseng HR. PMID: 19425037; PMCID: PMC2995451.
      View in: PubMed   Mentions: 38     Fields:    Translation:Animals
    256. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2009 Jan; 6(1):53-8. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS. PMID: 19015650; PMCID: PMC3526373.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansCells
    257. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J Nucl Med. 2008 Nov; 49(11):1828-35. Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA. PMID: 18927335.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    258. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008 Oct; 49(10):1579-84. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA. PMID: 18794268; PMCID: PMC4068272.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    259. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol. 2008 Nov-Dec; 10(6):341-8. Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. PMID: 18679756.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    260. Time-course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow. J Appl Clin Med Phys. 2008 Jun 23; 9(3):147-156. Kesner AL, Lau VK, Speiser M, Hsueh WA, Agazaryan N, DeMarco JJ, Czernin J, Silverman DH. PMID: 18716585; PMCID: PMC5722291.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    261. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008 Jul; 49(7):1038-46. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA. PMID: 18552153; PMCID: PMC4070847.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    262. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res. 2008 Jun 01; 14(11):3416-26. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. PMID: 18519772.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    263. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009 Aug; 71(2):242-8. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. PMID: 18511228.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    264. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am. 2008 Mar; 46(2):199-211, vii. Allen-Auerbach M, de Vos S, Czernin J. PMID: 18619376.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    265. Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nat Clin Pract Oncol. 2008 Mar; 5(3):160-70. Weber WA, Grosu AL, Czernin J. PMID: 18253106.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    266. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008 Jun; 35(6):1089-99. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. PMID: 18239919.
      View in: PubMed   Mentions: 47     Fields:    Translation:AnimalsCells
    267. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008 Feb 01; 14(3):715-20. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. PMID: 18245531.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    268. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol. 2008 Jan; 5(1):44-54. Weber WA, Czernin J, Phelps ME, Herschman HR. PMID: 18097456; PMCID: PMC2830564.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    269. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med. 2007 Dec; 48(12):2021-7. Kesner AL, Hsueh WA, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DH. PMID: 18006620.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    270. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007 Oct 20; 25(30):4714-21. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. PMID: 17947718.
      View in: PubMed   Mentions: 151     Fields:    Translation:Humans
    271. Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture? Clin Cancer Res. 2007 Jun 01; 13(11):3105-6. Weber WA, Czernin J, Phelps ME. PMID: 17545510.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    272. Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe. J Nucl Med. 2007 May; 48(5):776-82. Lin TW, de Aburto MA, Dahlbom M, Huang LL, Marvi MM, Tang M, Czernin J, Phelps ME, Silverman DH. PMID: 17475967.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    273. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007 Feb; 48(2):214-20. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. PMID: 17268017.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    274. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007 May; 62(2):199-204. Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. PMID: 17223003.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    275. PET/CT in cancer patient management. Introduction. J Nucl Med. 2007 Jan; 48 Suppl 1:2S-3S. Czernin J, Schelbert HR. PMID: 17204715.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    276. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007 Jan; 48 Suppl 1:78S-88S. Czernin J, Allen-Auerbach M, Schelbert HR. PMID: 17204723.
      View in: PubMed   Mentions: 123     Fields:    
    277. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med. 2006 Dec; 47(12):1995-9. Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, Phelps ME, Silverman DH. PMID: 17138742.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    278. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006 Oct 01; 12(19):5659-67. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. PMID: 17020967.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansAnimalsCells
    279. Semiautomated analysis of small-animal PET data. J Nucl Med. 2006 Jul; 47(7):1181-6. Kesner AL, Dahlbom M, Huang SC, Hsueh WA, Pio BS, Czernin J, Kreissl M, Wu HM, Silverman DH. PMID: 16818953.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    280. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006 Jun; 47(6):999-1006. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. PMID: 16741310.
      View in: PubMed   Mentions: 226     Fields:    Translation:Animals
    281. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006 Jun; 47(6):904-11. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. PMID: 16741298.
      View in: PubMed   Mentions: 163     Fields:    Translation:Humans
    282. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med. 2006 Feb; 47(2):298-301. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J. PMID: 16455636.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    283. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006 Feb; 129(2):393-401. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA. PMID: 16478857.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    284. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006; 57:99-118. Czernin J, Weber WA, Herschman HR. PMID: 16409139.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    285. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006 Jan-Feb; 8(1):36-42. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH. PMID: 16362149.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    286. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006 Jan; 12(1):122-7. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. PMID: 16341243.
      View in: PubMed   Mentions: 231     Fields:    Translation:HumansAnimalsCells
    287. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med. 2005 Nov; 46(11):1866-71. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, Silverman DH. PMID: 16269601.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    288. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005 Oct; 128(4):2289-97. Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, Czernin J. PMID: 16236886.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    289. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med. 2005 Sep; 46(9):1455-9. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DH. PMID: 16157527.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    290. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005 Sep-Oct; 7(5):369-76. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J. PMID: 16220355.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    291. Myocardial perfusion reserve in adults with cyanotic congenital heart disease. Am J Physiol Heart Circ Physiol. 2005 Nov; 289(5):H1798-806. Brunken RC, Perloff JK, Czernin J, Campisi R, Purcell S, Miner PD, Child JS, Schelbert HR. PMID: 16006539.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    292. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005 Jun; 46(6):945-52. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. PMID: 15937304.
      View in: PubMed   Mentions: 161     Fields:    Translation:Humans
    293. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med. 2005 Apr; 46(4):603-7. Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, Silverman DH, Ratib O, Czernin J. PMID: 15809482.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    294. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005 Apr; 46(4):587-95. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. PMID: 15809480.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    295. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med. 2005 Jan; 46(1):114-20. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J. PMID: 15632041.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    296. Clinical PET/CT imaging: promises and misconceptions. Nuklearmedizin. 2005; 44 Suppl 1:S18-23. Czernin J, Auerbach MA. PMID: 16395974.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    297. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol. 2004 Nov-Dec; 6(6):411-6. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. PMID: 15564152.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    298. Translational molecular imaging. Mol Imaging Biol. 2004 Jul-Aug; 6(4):181-2. Czernin J, Weber W. PMID: 15262232.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    299. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004 May; 45(5):797-801. Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, Ratib O, Czernin J. PMID: 15136629.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    300. The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor. Mol Imaging Biol. 2004 May-Jun; 6(3):126-30. Obrzut SL, Halpern BS, Monchamp T, Grabski K, Watts WJ, Czernin J. PMID: 15193246.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    301. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images. J Nucl Med. 2004 Feb; 45(2):290-3. Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, Ratib O, Czernin J. PMID: 14960650.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    302. Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease. Mol Imaging Biol. 2004 Jan-Feb; 6(1):47-54. Filmont JE, Yap CS, Ko F, Vranjesevic D, Quon A, Margolis DJ, Safaei A, Emmanouilides C, Silverman DH, Phelps ME, Czernin J. PMID: 15018828.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    303. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab. 2003 Nov; 80(3):350-5. Silverman DH, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. PMID: 14680983.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    304. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 2003 Aug; 124(2):608-13. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C. PMID: 12907550.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    305. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med. 2003 Aug; 44(8):1238-42. Vranjesevic D, Schiepers C, Silverman DH, Quon A, Villalpando J, Dahlbom M, Phelps ME, Czernin J. PMID: 12902413.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    306. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol. 2003 Jul-Aug; 5(4):271-7. Pio BS, Byrne FR, Aranda R, Boulay G, Spicher K, Song MH, Birnbaumer L, Phelps ME, Czernin J, Silverman DH. PMID: 14499142.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    307. Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients. Mol Imaging Biol. 2003 Jul-Aug; 5(4):232-9. Filmont JE, Vranjesevic D, Quon A, Margolis DJ, Ko F, Safaei A, Emmanouilides C, Silverman DH, Rao J, Valk PE, Phelps ME, Czernin J. PMID: 14499138.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    308. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003 Jun; 30 Suppl 1:S82-8. Schiepers C, Filmont JE, Czernin J. PMID: 12719922.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    309. Cigarette smoking and coronary blood flow. Prog Cardiovasc Dis. 2003 Mar-Apr; 45(5):395-404. Czernin J, Waldherr C. PMID: 12704596.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    310. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol. 2002 Jul; 4(4):283-93. Silverman DH, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, Phelps ME. PMID: 14537119.
      View in: PubMed   Mentions: 8     Fields:    
    311. A patient with primary cardiac lymphoma. Mol Imaging Biol. 2002 Jul; 4(4):274-5. Schöder H, Brown K, Said J, Czernin J. PMID: 14537116.
      View in: PubMed   Mentions:    Fields:    
    312. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective. Mol Imaging Biol. 2002 Mar; 4(2):185-90. Wong C, Silverman DH, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, Phelps ME, Rao J, Valk P, Czernin J. PMID: 14537142.
      View in: PubMed   Mentions: 4     Fields:    
    313. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002 Mar; 43(3):325-9. Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. PMID: 11884491.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    314. FDG-PET in breast cancer: a different view of its clinical usefulness. Mol Imaging Biol. 2002 Jan; 4(1):35-45. Czernin J. PMID: 14538047.
      View in: PubMed   Mentions: 6     Fields:    
    315. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002; 53:89-112. Czernin J, Phelps ME. PMID: 11818465.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    316. Clinical applications of FDG-PET in oncology. Acta Med Austriaca. 2002; 29(5):162-70. Czernin J. PMID: 12506767.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Johannes's Networks
    Concepts (642)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (144)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California